3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Neoplasms
805
Carcinoma, Non-Small-Cell Lung
767
Breast Neoplasms
731
Neoplasm Metastasis
340
Colorectal Neoplasms
339
Prostatic Neoplasms
324
Multiple Myeloma
309
Melanoma
305
Recurrence
237
Ovarian Neoplasms
236
Leukemia, Myeloid, Acute
236
Lymphoma, Non-Hodgkin
213
Lung Neoplasms
211
Carcinoma, Renal Cell
200
Lymphoma
189
Lymphoma, Follicular
163
Pancreatic Neoplasms
157
Leukemia, Lymphocytic, Chronic, B-Cell
149
Carcinoma, Hepatocellular
140
Stomach Neoplasms
137
Leukemia
133
Head and Neck Neoplasms
128
Lymphoma, Large B-Cell, Diffuse
126
Parkinson Disease 4, Autosomal Dominant Lewy Body
119
Squamous Cell Carcinoma of Head and Neck
110
Urinary Bladder Neoplasms
109
Carcinoma
101
Small Cell Lung Carcinoma
99
Triple Negative Breast Neoplasms
97
Glioblastoma
96
Interventions
tucatinib
1
pralsetinib
1
pertuzumab
1
ipatasertib
1
inavolisib
1
entrectinib
1
atezolizumab
1
alectinib
1
Trastuzumab
1
Tiragolumab
1
Paclitaxel
1
Ado-Trastuzumab Emtansine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Has results
×
Advanced Unresectable or Metastatic Solid Malignancy
×
Clear all
NCT04632992
2025-01-08
MyTACTIC
Genentech, Inc.
Phase 2
Completed
252 enrolled
27 charts